Evommune's EVO301 Shows 55% EASI Reduction in Phase 2a Atopic Dermatitis Data
EVMN is trading near its 52-week low of $8.11 (5.8% above the low).
Summary
Evommune presented detailed Phase 2a data for EVO301 in atopic dermatitis showing a 55% EASI reduction vs 22% placebo, with favorable safety and broad biomarker activity. A subcutaneous Phase 2b trial is planned for mid-2027.
Key Events · Product Development and Regulatory · EVMN
-
EVO301 Phase 2a Primary Endpoint Met
EVO301 achieved a 55% LS mean reduction in EASI at Week 12 vs 22% placebo (p<0.01), with separation from placebo as early as Week 4 (41% vs 18%).
-
EASI-50 and EASI-75 Response Rates
At Week 12, 63% of EVO301 patients achieved EASI-50 vs 23% placebo, and EASI-75 reached 29% vs 9% — comparable to marketed AD biologics after two doses.
-
Broad Biomarker Activity Confirmed
Exploratory analyses showed ~75% reduction in TARC (CCL-17) in high-baseline patients, plus reductions in Th1, Th17, and Th22 markers including IL-22.
-
Favorable Safety Profile
No treatment-related serious adverse events, no discontinuations, no conjunctivitis; treatment-related AEs in 10.4% of patients vs 13.6% placebo.
Analysis · EVMN · Life Sciences
Evommune presented full Phase 2a data for EVO301 at EADV 2026, showing a 55% reduction in EASI score versus 22% for placebo at Week 12 — a statistically significant result achieved with just two IV doses. The data validate IL-18 inhibition as a novel mechanism and support advancing to a subcutaneous Phase 2b trial in mid-2027. This matters because EVO301 is now the company's lead asset after EVO756 failed its Phase 2b atopic dermatitis trial in September 2026, making this the primary value driver for the pipeline.
How filings like this one have moved
In the 30 days to Nov 2, 2026, 32.7% of the 1910 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EVMN was trading at $8.58 on NYSE in the Life Sciences sector, with a market capitalization of approximately $299.8M. The 52-week trading range was $8.11 to $33.20. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.